ESMO 2012 was the stage for release of some key data in NSCLC and Prostate Cancer. Our team has measured the clinical impact of these presentations by pulsing the MDoutlook global network of 68,000 cancer treaters.
We are pleased to share the results with you! Click HERE to download a free report.
MDoutlook activities are predicated on 3 critical principles:
1) Relevant and accurate insight directly from pre-validated treaters;
2) Robust coverage and
3) Rapid response.
Insight is presented in reports that can be shared directly with senior management, and intelligence is enhanced by the review and feedback from key ThoughtLeaders in each disease covered.
Interested in learning more? Please contact me directly.
President, The Arcas Group